Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
Siyu GuYue HouKatarina DovatSinisa DovatChunhua SongZheng GePublished in: Experimental hematology & oncology (2023)
Our results demonstrated the synergistic effect of Chidamide with Cladribine on cell growth arrest, cell cycle arrest, and apoptosis in AML and primary cells with genetic defects by targeting HDAC2/c-Myc/RCC1 signaling in AML. Our data provide experimental evidence for the undergoing clinical trial (Clinical Trial ID: NCT05330364) of Chidamide plus Cladribine as a new potential regimen in AML.
Keyphrases
- cell cycle arrest
- clinical trial
- acute myeloid leukemia
- cell death
- pi k akt
- histone deacetylase
- allogeneic hematopoietic stem cell transplantation
- renal cell carcinoma
- phase ii
- study protocol
- open label
- double blind
- signaling pathway
- genome wide
- big data
- cell proliferation
- randomized controlled trial
- cancer therapy
- oxidative stress
- cell cycle
- drug delivery
- machine learning
- risk assessment
- human health
- induced apoptosis
- endoplasmic reticulum stress
- copy number